Aitia
Leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs
About Aitia
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.
Company Facts
- Headquarters
- Somerville
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- late_stage_venture
- Total Funding
- $77,264,920
- Last Funding Type
- series_d
- Last Funding Date
- 2019-07-09
- Website
- aitiabio.com
Industries & Categories
Big Data, Bioinformatics, Genetics
Social Links
Canonical: https://fsome.com/organization/aitia-35316 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.